ARV Technologies

ARV Technologies, which now brands its platform and pipeline as Pinion Immunotherapeutics, is a private biotechnology company developing AI-driven mRNA immunotherapies for chronic viral infections and virus-driven cancers. The company focuses on antigen design, mRNA engineering, and proprietary lipid nanoparticle delivery to drive both CD8+ T-cell responses and neutralizing antibody responses. Its disclosed pipeline includes programs in HPV-16 precancer, acute myeloid leukemia, Epstein-Barr virus, and hepatitis B, with ARV-2001 described as IND-cleared and Phase I enrollment targeted for 2026. ARV Technologies presents itself as a lean Maryland-based company with operations in the U.S. and Suzhou, China, and emphasizes capital-efficient development of immunotherapy and vaccine assets.